GSK acted “after lying in wait, and abusing the patent system” to “siphon resources and earnings” for Moderna’s “lauded efforts to address a global pandemic,” according to Moderna’s answer and counterclaims filed Thursday in the US District Court for the District of Delaware.
GSK is trying to do “in the courtroom what it could not accomplish (and, in fact, failed to do) in the laboratory, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
